Battery explantation after sacral neuromodulation in the medicare population by Cameron, Anne P. et al.
Neurourology and Urodynamics 32:238–241 (2013)
Battery Explantation After Sacral Neuromodulation in
the Medicare Population
Anne P. Cameron,1* Jennifer T. Anger,2 Rodger Madison,3 Christopher S. Saigal,4 J. Quentin Clemens1
and the Urologic Diseases in America Project
1Department of Urology, University of Michigan, Ann Arbor, Michigan
2Cedars-Sinai Medical Center, Los Angeles, California
3RAND Corporation, Los Angeles, California
4Department of Urology, University of California in Los Angeles, Los Angeles, California
Aims: To determine sacral neuromodulation battery life and the patient and provider risk factors for early explan-
tation in a population-based sample. Methods: A 5% sample of Medicare beneficiaries from 1997 to 2007 served as the
data source. All patients who had a sacral neuromodulation device implanted in that time period were included. Varia-
bles included in a multivariate analysis of risk factors for removal included gender, age, race, diagnosis, type of test
phase, provider specialty, and volume. The number of device reprogramming events was also recorded in this time
period. Results: Mean follow-up was 60.5 months. Patients on average had 2.15 reprogramming episodes in their first
year, with that number decreasing over subsequent years. Out of the 558 batteries implanted 63 (11.3%) were
explanted. Of the 19 implanted individuals who carried the diagnosis of interstitial cystitis (IC), 11 (57.9%) had the
battery removed. This was the only variable that predicted early removal, with an odds ratio of explantation of 10.5
(95% CI: 3.9–28.4). Conclusion: Very few sacral neuromodulation batteries, once implanted, are removed prematurely.
Patients with IC, however, are at very high risk of requiring premature battery removal. Neurourol. Urodynam.
32:238–241, 2013.  2012 Wiley Periodicals, Inc.
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INTRODUCTION
Sacral neuromodulation is increasing in popularity for the
treatment of medically refractory bladder symptoms, with
over 100,0001 devices implanted worldwide since FDA approv-
al in 1997. The manufacturer lists the battery life for the origi-
nal model as 7 years (5.5–9.2) and the newer smaller model at
4.4 years (2.5–5.4).1
It is unknown, however, how well these batteries perform
outside of manufacturer trials and how many of these devices
are removed prematurely. In small trials actual battery lon-
gevity has been similar to those listed by the manufacturer,2
but removal can be performed for infection, damage to device,
site pain, poor clinical response, need for MRI, and battery
depletion.3–5 It is unknown which individuals are at higher
risk for the need for removal, but studies suggest that
more revisions are performed on devices implanted earlier
in the learning curve of the device,4 and in those who had
percutaneous tests compared to staged testing with the
tined lead,5 but these results are not universal.2 Certain
urological diagnoses may increase one’s risk of device explan-
tation. Interstitial cystitis (IC) patients over the long-term
had a 50% explantation rate in one study, but in another
study of exclusively IC patients there were no explantations
reported.2,6 It is also unknown how frequently patients
require device reprogramming and if this has any impact on
device survival.
Our goal in this analysis was to identify the explantation
and device reprogramming rate over the long-term and to
identify patient and provider risk factors for early explantation.
MATERIALS AND METHODS
A 5% sample of Medicare beneficiaries from 1997 to 2007
was the data source utilized. All patients in the sample who
had a sacral neuromodulation battery implantation identified
using CPT code 64590 (insertion or replacement of peripheral
or gastric neurostimulator pulse generator or receiver) and
had a urological diagnosis associated with this procedure
were included in the analysis. Any patient who had their
battery explanted within 90 days was excluded since this was
likely due to infection or early device malfunction (n ¼ 3,
4.8%). For analysis purposes, patients were divided into five
mutually exclusive diagnosis groups based on the first two
ICD-9 diagnostic codes linked to the battery implantation.
Any patient with a neurogenic bladder diagnosis (NGB) was
placed in the neurogenic category; those with IC were placed
in the IC group unless they had a diagnosis of NGB. Those
with incomplete bladder emptying or non-obstructive urinary
retention were placed in the retention group unless they had
IC or NGB. Those with urgency incontinence or other forms of
incontinence except stress incontinence were placed in the
‘‘wet’’ overactive bladder (OAB) group unless they had one of
the preceding diagnoses. The remaining persons with urgency,
frequency, and nocturia were placed in the ‘‘dry’’ OAB group
since they did not have a diagnosis of incontinence. All other
urologic diagnosis associated with a procedure that did not fit
into one of the above-mentioned categories were grouped into
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the ‘‘other’’ category. Any person who had no urologic diagnosis
whatsoever associated with their procedure was excluded since
these were likely other types of neuromodulating devices.
Medicare demographic data were also utilized to determine
patient age and race/ethnicity. The specialty of the provider
who performed the implant was taken from the CMS claim
line item for the procedure. Physicians were tracked by their
unique physician identification number (UPIN) and the sur-
geon volume was determined for each provider and divided
into high and low volume based on the number of implants
performed in the entire period (1997–2007). Those surgeons in
the 75th percentile and above of surgical procedures were
deemed to be ‘‘high volume.’’ The implant was considered
to be preceded by a percutaneous test if the patient under-
went a percutaneous test (64561) followed by a simultaneous
permanent lead and battery implant (64581 þ 64590).
Patients who had a permanent lead placed (64581) followed
by a device implant at a later date (64590) were considered to
be a two-staged procedure. Any patient who did not have a
battery explantation identified by code 64595 (revision or
removal of peripheral or gastric neurostimulator pulse genera-
tor or receiver) at any point during follow up was considered
to have a working implant.
Reprogramming events of the device (95972) were recorded
at yearly intervals following implant. For those patients who
had a device removed, the number of reprogramming events
was recorded in the 12 months before explantation. The
reprograming event numbers were compared between patient
groups using an unpaired t-test.
Initial data on the success of test stimulation in this popula-
tion has previously been reported.7 A multivariate logistic
regression was carried out to determine those patient or pro-
vider factors that increase the risk of battery removal.
Kaplan–Meier curve was created to determine battery survival
over time with a battery explantation deemed as battery
failure with patient mortality accounted for in calculations.
RESULTS
In total there were 561 battery implants from 1997 to 2007.
81.5% of the population was female and 92.6% Caucasian.
Three implants were removed within 90 days (4.8%) and
were excluded leaving 558 implants evaluable. At the end of
follow-up (mean 60.5 months) 89.7% of implants were still in
place (Fig. 1) with a total of 63 explantations. Mean time to
explantation could not be calculated given the small number
of explants in the group. These results did not change even
after accounting for patient mortality (n ¼ 27) during the
follow-up period.
Of the 63 devices explanted seven (11.1%) had a new battery
implanted on the same day as explant. Out of these six had
urgency incontinence and only one had IC.
Reprogramming occurred on average 2.15 times the first
year after implant, 0.70 times year 2, 0.65 time year 3, 0.48
times year 4, and 0.36 times year 5. There were no differences
in the number of reprogramming events based on age or type
of test phase. However, compared to the reference diagnosis
of IC, individuals who were implanted with a diagnosis of
NGB or OAB both wet and dry were reprogrammed more
frequently. In the year before device explant patients had
their device reprogrammed a mean of 0.35 times with no
difference in the number of reprogramming events among
any of the groups except IC who had zero reprogrammings
(Table I).
On multivariate analysis (including the variables of provider
volume, provider specialty, type of test phase, patient age,
diagnosis, gender, and race), none reached statistical signifi-
cance except IC as a diagnosis. Eleven of 19 (57.9%) batteries
implanted for IC were removed and the odds of explantation
for IC was 10.5 (95% CI: 3.9–28.4; Table II).
DISCUSSION
These findings suggest that sacral neuromodulation im-
plantable devices are infrequently removed, with only 10.3%
of batteries removed in the 60.5 months timeframe among a
5% sample of the Medicare dataset. Devices were reprog-
rammed most frequently in the year following implant, but
surprisingly patients only had their device reprogrammed
0.35 on average in the year prior to explantation.
Ninety days was chosen as the cutoff for explantation due
to infection. All three of these very early device removals were
Fig. 1. Kaplan–Meier estimator for battery explantation.
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within the first 30 days of implant. These results are compara-
ble to other large series where infections occurred in 3.5% at a
mean of 16.5 days after device implant.8
Seven patients who had their device removed (11.1%) had a
new device implanted on the same day. Clinically, this would
be performed in cases of battery depletion or device breakage
or malfunction and not in cases of inefficacy or pain from the
device. Only one of these seven patients carried the diagnosis
of IC. Other studies have shown similar results with low
explantation rates of 9.8–14.1% for urgency incontinence,
urgency/frequency syndrome, and non-obstructive urinary re-
tention.3–5,9,10 In these studies the majority of explantations
were performed for loss of efficacy or device infection. In three
long-term studies of device complications,2–4 the reported rate
of infection was 4–17%, loss of efficacy 0–28%, device damage
2–4%, lead migration 3–8%, and hematoma/seroma 10%. Pain
at the site of the device was reported between 15% and 53%
and new onset pain 0–43%. Unfortunately we were not able
to determine the reason for battery explantation in our series.
Patients in this study with a diagnosis of IC fared poorly
with a 57.9% explantation rate. In this analysis, IC was the
only identifiable risk factor for early battery removal. Assum-
ing that these individuals do not have a greater risk of infec-
tion than others, one would have to presume that the
majority of these explants were for lack of efficacy or new
pain at the device site, and since only one of these patients
had a new device implanted when the device was removed
this assumption is likely. Others have evaluated the long-term
results of sacral neuromodulation devices in patients with IC.
In a study of 17 individuals with IC implanted with a neuro-
stimulator, none required revision or explantation over an
average of 14 months.6 In a group of 46 individuals with
painful bladder syndrome/IC, 28% were explanted mostly for
poor efficacy and 50% required revisions over 61.5 months.11
In another study of exclusively IC patients followed an aver-
age of 60 months, 11 of the 22 patients required explantation
for battery depletion (4), ineffectiveness (3), infection (1), and
other reasons (3).2 The authors felt that, despite the high
explantation rate, the long-term effectiveness of the device
was good with no decrease in benefits for 86% of patients at
59.9 months.
Perhaps patients with IC in this series fared so poorly long-
term because the S3 nerve root stimulation is not the ideal
route for neuromodulation and they are better treated with
stimulation of another nerve. In a prospective trial with 17 IC
patients with an implanted battery stimulated with either a
standard sacral lead or a pudendal nerve lead, Peters et al.12
found more improvements in urgency and frequency at
6 months with the pudendal stimulation but no difference in
pain. Zabihi et al.13 had a 42% success rate in treating both pain
and voiding symptoms in a group of 23 individuals with chronic
pelvic pain or IC who had already failed traditional S3 sacral
neuromodulation with bilateral S2–S4 neuromodulation.
In this series patient who had a two-staged test did not
have better device survival than patients who had a percuta-
neous tests and did not require more reprogramming events.
This is in contrast to the findings of a retrospective series of
104 patients with an equal number of two-staged tests and
percutaneous tests where lack of efficacy was reported three
times higher in patients who had the percutaneous test.5
These patients, however, all were implanted with the older
non-tined lead which may be the contributing factor, not the
type of test. A more recent series did not report a difference in
device revisions between the two test types.2
TABLE I. Sacral Neuromodulation Device Reprogramming Events After Implantation and 12 Months Before Explantation
Effect
First year
(n ¼ 558) P-valuea Second year Third year Fourth year Fifth year
In year prior to
explantb (n ¼ 63) P-value
Total 2.15 — 0.70 0.65 0.48 0.36 0.35 —
Percutaneous test 2.04 Ref. 0.69 0.56 0.31 0.00 0.35 Ref.
Two-stage test 2.20 0.34 0.71 0.71 0.60 0.60 0.36 0.49
Interstitial cystitis 1.49 Ref. 0.27 0.69 0.78 0.87 0.00 —
Neurogenic bladder 2.37 0.011 0.72 0.34 0.97 1.13 0.73 0.22
Retention 2.07 0.053 0.65 0.54 0.30 0.11 0.22 0.54
Overactive bladder wet 2.14 0.038 0.74 0.77 0.54 0.24 0.26 Ref.
Overactive bladder dry 2.26 0.019 0.72 0.55 0.33 0.50 0.95 0.15
aIncludes only first year, insufficient data to compare second through fifth year.
bIncludes only patients who were explanted.
TABLE II. Patient and Provider Variable’s Impact on Sacral Neuromodulation Device Explantation
Effect Explanted devices Odds ratio of removal 95% Confidence limit
High volume provider versus low volume provider 29/256 (11.3%) 34/302 (11.3%) 1.10 0.63–1.93
Urologist versus other surgeon 53/461 (11.5%) 10/97 (10.3%) 1.20 0.56–2.56
Percutaneous test versus two-stage test 45/365 (12.3%) 18/193 (9.3%) 0.69 0.38–1.27
Caucasian versus other races 58/517 (11.2%) 5/41 (12.2%) 0.81 0.29–2.27
Female versus male 56/455 (12.3%) 7/103 (6.8%) 1.94 0.82–4.57
Age 75 versus >75 46/369 (12.5%) 17/189 (9.0%) 1.19 0.64–2.21
Diagnosis versus all others
Neurogenic bladder 5/26 (19.2%) 2.27 0.78–6.65
Interstitial cystitis 11/19 (57.9%) 10.48 3.86–28.5
Retention 5/69 (7.3%) 0.64 0.24–1.73
Overactive bladder wet 32/294 (10.9%) 0.61 0.29–1.29
Overactive bladder dry 10/115 (8.7%) 0.60 0.22–1.11
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The finding of reprograming episodes occurring most fre-
quently in the first year after implant is not surprising since
this is a new device for the patient that can often be opti-
mized soon after implant with device reprogrammings. The
lack of reprogramming episodes in the year prior to explant,
however, is surprising since lack of efficacy is often initially
treated with a change in device settings to improve the clini-
cal situation.1,14
It is possible that patients had exhausted all reprogram-
ming options prior to device removal; however, waiting
12 months after reprogramming to have an ineffective device
removed seems unlikely. Perhaps those patients who had
devices explanted were not offered reprogramming as an
option or had the device explanted for pain, which is not typi-
cally treated with reprogramming. Given that the majority of
explants were for IC which is a chronic pain condition and
that this patient population had the fewest reprogramming
episodes in the year prior to explant, the latter is certainly
likely.
There are several limitations to this analysis. There are
inherent problems with utilizing billing data to determine
patient outcomes. Coding of diagnosis and procedures is not
always accurate, but given that there is only one possible CPT
code for battery implantation (64590) and one for removal
(64595), and that accurate coding is essential for reimburse-
ment, it is unlikely that procedure coding would be erroneous.
There is however the possibility that an individual could have
their battery removed under a different type of insurance, and
would not be captured in this dataset. However, this is also
likely to be uncommon.
Medicare patients as a whole are a more elderly population,
hence these results may not be generalizable to the general
population, but the explantation rate is comparable to other
series with mixed age populations. Therefore, there is no rea-
son to believe that the elderly have a greater rate of explan-
tation. The major limitation of this analysis is the assumption
that a device is still functional if it has not been explanted.
Many individuals lose efficacy, but may elect not to have the
device explanted since it is causing no symptoms and this
would require another surgery. With no clinical information
about bladder symptoms we cannot estimate this number.
Also, for those individuals who did have their device
explanted, we do not know the clinical reasons for the failure.
We assume that the device was indeed removed for a failure,
but the need for an MRI or spontaneous resolution of their
symptoms is not a device failure per se, but may have been
coded as such in this analysis.
CONCLUSIONS
Very few sacral neuromodulation batteries once implanted
are removed prematurely. Patients with IC, however, are at
very high risk of requiring a battery removal likely due to
pain or device non-efficacy.
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